Myocardial Neprilysin Is Increased in Hypertrophic Cardiomyopathy.

In patients with end-stage nonobstructive HCM and dilated cardiomyopathy at the time of transplant, single nucleus RNA sequencing revealed higher I MME i expression only in fibroblasts, and the degree of I MME i elevation was not significantly different in end-stage nonobstructive HCM versus dilated cardiomyopathy (). Footnotes 1 Nonstandard Abbreviations and Acronyms ARNi angiotensin receptor blocker/neprilysin inhibitor EF ejection fraction HCM hypertrophic cardiomyopathy HF heart failure MME membrane metalloendopeptidase NEP neprilysin oHCM obstructive hypertrophic cardiomyopathy 2 For Sources of Funding and Disclosures, see page 169. Keywords: cardiomyopathy, hypertrophic; heart failure; neprilysin EN cardiomyopathy, hypertrophic heart failure neprilysin 167 169 3 07/07/23 20230711 NES 230711 A frequent narrative is that no medical therapy modifies the natural history of hypertrophic cardiomyopathy (HCM), but evidence shows valsartan and mavacamten modify disease progression in HCM. [Extracted from the article]